ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis

Breast Cancer is the leading cause of Cancer death in female. Until now, advanced breast Cancer is still lack effective treatment strategies and reliable prognostic markers. In the present article, we introduced the physiologic and pathologic functions and regulation mechanisms of ZBTB28, a tumor suppressor gene, in breast Cancer. ZBTB28 is frequently silenced in breast Cancer due to promoter CpG methylation, and its expression is positively correlated with breast Cancer patient survival. The antineoplastic effect of ZBTB28 in breast Cancer was elucidated through a series of in vitro and in vivo measurements, including cell proliferation, Apoptosis, cell cycle, epithelial mesenchymal transition (EMT), and growth of xenografts. Furthermore, ZBTB28 can directly regulate IFNAR to activate interferon-stimulated genes and potentiate macrophage activation. Ectopic ZBTB28 expression in breast Cancer cells was sufficient to downregulate CD24 and CD47 to promote phagocytosis of macrophages, demonstrating that ZBTB28 was beneficial for the combination treatment of anti-CD24 and anti-CD47. Collectively, our results reveal a mode of action of ZBTB28 as a tumor suppressor gene and suggest that ZBTB28 is an important regulator of macrophage phagocytosis in breast Cancer, holding promise for the development of novel therapy strategies for breast Cancer patients.